New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 5, 2013
08:10 EDTCLVSClovis shares should be bought on weakness, says Leerink
After consulting with experts, Leerink believes that the potential for Clovis' CO-1686 front-line non- small cell lung cancer treatment, which has a benign safety profile versus the standard of care, has been underappreciated. The firm thinks the drug could generate more than $1.5B in peak sales, and it reiterates a $94 price target and Outperform rating on the stock.
News For CLVS From The Last 14 Days
Check below for free stories on CLVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
11:01 EDTCLVSClovis volatility increases on wide price movement
Subscribe for More Information
April 10, 2014
10:24 EDTCLVSClovis volatility elevated
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use